{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:58:45Z","timestamp":1791921525233,"version":"4.3.4"},"reference-count":72,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Mundipharma Global"},{"name":"Ashfield MedComms GmbH"},{"DOI":"10.13039\/100014471","name":"Mundipharma Research Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014471","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Echinocandin drugs are the current first-line therapy for fungal infections caused by Candida spp. Most patients require once-daily intravenous (IV) administration in a hospital or outpatient setting for treatment, which may negatively impact their quality of life and stress healthcare resources. Similar to other echinocandins, the novel FDA-, EMA-, and Medical and Healthcare Products Regulatory Agency-approved echinocandin, rezafungin (CD101), exhibited strong antifungal activity against several fungal pathogens and a low drug\u2013drug interaction liability, which are important for medically complex patients. A pharmacometric-based approach has been adopted throughout the development of rezafungin, which contrasts with older echinocandins where dosing regimens were largely derived empirically, and only recently based on pharmacometric guidance. This state-of-the-art approach used model-based simulations incorporating pre-clinical and clinical data as it became available to optimize the dosing regimen for rezafungin. The enhanced stability of the molecular structure and the safety profile of rezafungin allow for the administration of once-weekly IV doses, compared to the daily dosing requirement for other echinocandin drugs, with this distinctive pharmacokinetic profile of rezafungin resulting in a front-loaded dosing regimen with high exposures early in therapy for enhanced fungal killing. The long shelf-life of rezafungin makes this echinocandin more flexible in terms of storage and manufacturing. Demonstrated across clinical development, rezafungin may provide patients with next-generation first-line antifungal treatment for the treatment of candidaemia and invasive candidiasis.<\/jats:p>","DOI":"10.1093\/jac\/dkae415","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T16:17:36Z","timestamp":1730391456000},"page":"18-28","source":"Crossref","is-referenced-by-count":25,"title":["The distinctive pharmacokinetic profile of rezafungin, a long-acting echinocandin developed in the era of modern pharmacometrics"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7927-9950","authenticated-orcid":false,"given":"David","family":"Andes","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Wisconsin School of Medicine and Public Health , Madison, WI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7618-725X","authenticated-orcid":false,"given":"Roger J","family":"Br\u00fcggemann","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Radboudumc Institute for Medical Innovation, Radboud University Medical Center, and Radboudumc-CWZ Nijmegen Center of Expertise in Mycology , Nijmegen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Flanagan","sequence":"additional","affiliation":[{"name":"Cidara Therapeutics , San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9299-3027","authenticated-orcid":false,"given":"Alexander J","family":"Lepak","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Wisconsin School of Medicine and Public Health , Madison, WI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2002-4339","authenticated-orcid":false,"given":"Russell E","family":"Lewis","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, University of Padua , Padua ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Voon","family":"Ong","sequence":"additional","affiliation":[{"name":"Cidara Therapeutics , San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M","family":"Rubino","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc. , Schenectady, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Sandison","sequence":"additional","affiliation":[{"name":"Cidara Therapeutics , San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,14]]},"reference":[{"key":"2025010610354860900_dkae415-B1","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3389\/fmicb.2019.00214","article-title":"The still underestimated problem of fungal diseases worldwide","volume":"10","author":"Almeida","year":"2019","journal-title":"Front Microbiol"},{"key":"2025010610354860900_dkae415-B2","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/nrmicro862","article-title":"Antimicrobial pharmacodynamics: critical interactions of \u2018bug and drug\u2019","volume":"2","author":"Drusano","year":"2004","journal-title":"Nat Rev Microbiol"},{"key":"2025010610354860900_dkae415-B3","doi-asserted-by":"publisher","first-page":"4619","DOI":"10.1128\/AAC.00182-11","article-title":"Pharmacokinetic\/pharmacodynamic (PK\/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization","volume":"55","author":"Nielsen","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2025010610354860900_dkae415-B4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1586\/ecp.13.6","article-title":"Applications of pharmacometrics in the clinical development and pharmacotherapy of anti-infectives","volume":"6","author":"Trivedi","year":"2013","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2025010610354860900_dkae415-B5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1086\/596757","article-title":"Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America","volume":"48","author":"Pappas","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2025010610354860900_dkae415-B6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/cid\/civ1194","article-title":"Executive summary: clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"Suppl 7","key":"2025010610354860900_dkae415-B7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/1469-0691.12039","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients","volume":"18","author":"Cornely","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2025010610354860900_dkae415-B8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1039\/C3NP70070D","article-title":"Discovery and development of first in class antifungal caspofungin (CANCIDAS\u00ae)\u2014a case study","volume":"31","author":"Balkovec","year":"2014","journal-title":"Nat Prod Rep"},{"issue":"Suppl 6","key":"2025010610354860900_dkae415-B9","doi-asserted-by":"publisher","first-page":"S635","DOI":"10.1093\/cid\/civ715","article-title":"Single or 2-dose micafungin regimen for treatment of invasive candidiasis: therapia sterilisans magna!","volume":"61","author":"Gumbo","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2025010610354860900_dkae415-B10","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1128\/AAC.02124-15","article-title":"Efficacy of extended-interval dosing of micafungin evaluated using a pharmacokinetic\/pharmacodynamic study with humanized doses in mice","volume":"60","author":"Lepak","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2025010610354860900_dkae415-B11","doi-asserted-by":"publisher","first-page":"i44","DOI":"10.1093\/jac\/dkx448","article-title":"We can do better: a fresh look at echinocandin dosing","volume":"73","author":"Bader","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2025010610354860900_dkae415-B12","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1128\/AAC.01337-06","article-title":"Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia","volume":"51","author":"Gumbo","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 6","key":"2025010610354860900_dkae415-B13","doi-asserted-by":"publisher","first-page":"S643","DOI":"10.1093\/cid\/civ817","article-title":"Intermittent dosing of micafungin is effective for treatment of experimental disseminated candidiasis in persistently neutropenic rabbits","volume":"61","author":"Petraitiene","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2025010610354860900_dkae415-B14","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1086\/598933","article-title":"A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis","volume":"48","author":"Betts","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2025010610354860900_dkae415-B15","doi-asserted-by":"publisher","first-page":"107058","DOI":"10.1016\/j.ijantimicag.2023.107058","article-title":"Micafungin twice-a-week for prophylaxis of invasive Aspergillus infections in children with acute lymphoblastic leukaemia: a controlled cohort study","volume":"63","author":"Bury","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"2025010610354860900_dkae415-B16","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1093\/ofid\/ofy358","article-title":"Twenty years of the SENTRY antifungal surveillance program: results for Candida species from 1997-2016","volume":"6","author":"Pfaller","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2025010610354860900_dkae415-B17","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/mmy\/myz053","article-title":"Resistance to echinocandin antifungal agents in the United Kingdom in clinical isolates of Candida glabrata: fifteen years of interpretation and assessment","volume":"58","author":"Fraser","year":"2020","journal-title":"Med Mycol"},{"key":"2025010610354860900_dkae415-B18","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1093\/jac\/dkac288","article-title":"Blood and intra-abdominal Candida spp. from a multicentre study conducted in Madrid using EUCAST: emergence of fluconazole resistance in Candida parapsilosis, low echinocandin resistance and absence of Candida auris","volume":"77","author":"D\u00edaz-Garc\u00eda","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2025010610354860900_dkae415-B19","doi-asserted-by":"publisher","first-page":"e0005322","DOI":"10.1128\/aac.00053-22","article-title":"Candida auris pan-drug-resistant to four classes of antifungal agents","volume":"66","author":"Jacobs","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2025010610354860900_dkae415-B20","doi-asserted-by":"publisher","first-page":"e0224221","DOI":"10.1128\/aac.02242-21","article-title":"Antifungal resistance trends of Candida auris clinical isolates in New York and New Jersey from 2016 to 2020","volume":"66","author":"Kilburn","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2025010610354860900_dkae415-B21","doi-asserted-by":"publisher","first-page":"e01627-16","DOI":"10.1128\/AAC.01627-16","article-title":"Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults","volume":"61","author":"Sandison","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025010610354860900_dkae415-B22","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3390\/jof6040262","article-title":"Rezafungin-mechanisms of action, susceptibility and resistance: similarities and differences with the other echinocandins","volume":"6","author":"Garcia-Effron","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"2025010610354860900_dkae415-B23","article-title":"US Prescribing Infromation. REZZAYO\u2122 (Rezafungin for Injection), for Intravenous Use Initial U.S. Approval","author":"Cidara Therapeutics I","year":"2023"},{"key":"2025010610354860900_dkae415-B24","author":"European Medicines Agency"},{"key":"2025010610354860900_dkae415-B25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00253-020-11022-y","article-title":"Echinocandins: structural diversity, biosynthesis, and development of antimycotics","volume":"105","author":"H\u00fcttel","year":"2021","journal-title":"Appl Microbiol Biotechnol"},{"key":"2025010610354860900_dkae415-B26","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1080\/14756366.2022.2050224","article-title":"Echinocandins\u2014structure, mechanism of action and use in antifungal therapy","volume":"37","author":"Szyma\u0144ski","year":"2022","journal-title":"J Enzyme Inhib Med Chem"},{"key":"2025010610354860900_dkae415-B27","doi-asserted-by":"publisher","first-page":"e8524","DOI":"10.1371\/journal.pone.0008524","article-title":"Echinocandin treatment of Pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection","volume":"5","author":"Cushion","year":"2010","journal-title":"PLoS One"},{"key":"2025010610354860900_dkae415-B28","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jgar.2018.02.013","article-title":"Rezafungin (CD101), a next-generation echinocandin: a systematic literature review and assessment of possible place in therapy","volume":"14","author":"Sofjan","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"key":"2025010610354860900_dkae415-B29","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2147\/tcrm.2007.3.1.71","article-title":"Comparison of echinocandin antifungals","volume":"3","author":"Eschenauer","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"2025010610354860900_dkae415-B30","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1128\/CMR.00046-13","article-title":"Tissue penetration of antifungal agents","volume":"27","author":"Felton","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"2025010610354860900_dkae415-B31","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/S0140-6736(03)14472-8","article-title":"Echinocandin antifungal drugs","volume":"362","author":"Denning","year":"2003","journal-title":"Lancet"},{"key":"2025010610354860900_dkae415-B32","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ccc.2010.11.001","article-title":"Fungal sepsis: optimizing antifungal therapy in the critical care setting","volume":"27","author":"Lepak","year":"2011","journal-title":"Crit Care Clin"},{"key":"2025010610354860900_dkae415-B33","doi-asserted-by":"publisher","first-page":"a019653","DOI":"10.1101\/cshperspect.a019653","article-title":"Antifungal pharmacokinetics and pharmacodynamics","volume":"5","author":"Lepak","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2025010610354860900_dkae415-B34","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2217\/fmb.11.19","article-title":"Current perspectives on echinocandin class drugs","volume":"6","author":"Perlin","year":"2011","journal-title":"Future Microbiol"},{"key":"2025010610354860900_dkae415-B35","doi-asserted-by":"publisher","first-page":"e00546","DOI":"10.1002\/prp2.546","article-title":"Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: insights on the PK\/PD pharmacometrics of rezafungin efficacy","volume":"7","author":"Miesel","year":"2019","journal-title":"Pharmacol Res Perspect"},{"key":"2025010610354860900_dkae415-B36","article-title":"Pharmacokinetics pharmacodynamics (PKPD) of a novel echinocandin, CD101, in a neutropenic murine disseminated candidiasis model","author":"Rubino"},{"key":"2025010610354860900_dkae415-B37","doi-asserted-by":"publisher","first-page":"e00758-17","DOI":"10.1128\/AAC.00758-17","article-title":"Pharmacological basis of CD101 efficacy: exposure shape matters","volume":"61","author":"Lakota","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025010610354860900_dkae415-B38","doi-asserted-by":"publisher","first-page":"e02154-17","DOI":"10.1128\/AAC.02154-17","article-title":"Pharmacodynamics of a long-acting echinocandin, CD101, in a neutropenic invasive-candidiasis murine model using an extended-interval dosing design","volume":"62","author":"Lepak","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2025010610354860900_dkae415-B39","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1128\/AAC.01584-09","article-title":"In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species","volume":"54","author":"Andes","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2025010610354860900_dkae415-B40","doi-asserted-by":"publisher","first-page":"e01572-18","DOI":"10.1128\/AAC.01572-18","article-title":"Pharmacodynamic evaluation of rezafungin (CD101) against Candida auris in the neutropenic mouse invasive candidiasis model","volume":"62","author":"Lepak","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2025010610354860900_dkae415-B41","doi-asserted-by":"publisher","first-page":"e01556-19","DOI":"10.1128\/AAC.01556-19","article-title":"Determination of pharmacodynamic target exposures for rezafungin against Candida tropicalis and Candida dubliniensis in the neutropenic mouse disseminated candidiasis model","volume":"63","author":"Lepak","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2025010610354860900_dkae415-B42","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.drup.2011.01.004","article-title":"Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria","volume":"14","author":"Pfaller","year":"2011","journal-title":"Drug Resist Update"},{"key":"2025010610354860900_dkae415-B43","doi-asserted-by":"publisher","first-page":"e02603-17","DOI":"10.1128\/AAC.02603-17","article-title":"Population pharmacokinetic analyses for rezafungin (CD101) efficacy using phase 1 data","volume":"62","author":"Lakota","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2025010610354860900_dkae415-B44","doi-asserted-by":"publisher","first-page":"e02614-17","DOI":"10.1128\/AAC.02614-17","article-title":"Overcoming the resistance hurdle: pharmacokinetic-pharmacodynamic target attainment analyses for rezafungin (CD101) against Candida albicans and Candida glabrata","volume":"62","author":"Bader","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2025010610354860900_dkae415-B45","doi-asserted-by":"publisher","first-page":"e0084221","DOI":"10.1128\/AAC.00842-21","article-title":"Population pharmacokinetics of rezafungin in patients with fungal infections","volume":"65","author":"Rubino","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2025010610354860900_dkae415-B46","volume-title":"Pharmacokinetic-Pharmacodynamic (PK-PD) target attainment analyses to support rezafungin (RZF) dose selection in treatment of Candida","author":"Lakota","year":"2018"},{"key":"2025010610354860900_dkae415-B47","volume-title":"Pharmacokinetic-pharmacodynamic target attainment analyses to support rezafungin dose selection in the treatment of Candida infections","author":"Lakota","year":"2018"},{"key":"2025010610354860900_dkae415-B48","volume-title":"Population pharmacokinetic and pharmacokinetic-pharmacodynamic target attainment analyses for rezafungin for treatment of Candida infections","author":"Lakota","year":"2019"},{"key":"2025010610354860900_dkae415-B49","doi-asserted-by":"publisher","first-page":"e00916-23","DOI":"10.1128\/aac.00916-23","article-title":"Population pharmacokinetic modeling and target attainment analyses of rezafungin for the treatment of candidemia and invasive candidiasis","volume":"67","author":"Roepcke","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2025010610354860900_dkae415-B50","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/0010-468X(79)90025-4","article-title":"A program package for simulation and parameter estimation in pharmacokinetic systems","volume":"9","author":"D'Argenio","year":"1979","journal-title":"Comput Programs Biomed"},{"key":"2025010610354860900_dkae415-B51","doi-asserted-by":"publisher","first-page":"E60","DOI":"10.1208\/aapsj0901007","article-title":"A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples","volume":"9","author":"Bauer","year":"2007","journal-title":"AAPS J"},{"key":"2025010610354860900_dkae415-B52","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1177\/0091270004265644","article-title":"Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal","volume":"44","author":"Dowell","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"2025010610354860900_dkae415-B53","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1128\/AAC.01912-12","article-title":"Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosis","volume":"57","author":"W\u00fcrthwein","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2025010610354860900_dkae415-B54","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2133\/dmpk.24.25","article-title":"Mechanistic basis of using body size and maturation to predict clearance in humans","volume":"24","author":"Anderson","year":"2009","journal-title":"Drug Metab Pharmacokinet"},{"key":"2025010610354860900_dkae415-B55","volume-title":"Rezafungin (CD101) prophylactic dose rationale for prevention of Aspergillus, Candida, and Pneumocystis infections","author":"Flanagan","year":"2018"},{"key":"2025010610354860900_dkae415-B56","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.ijantimicag.2017.03.028","article-title":"CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance Program","volume":"50","author":"Pfaller","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"2025010610354860900_dkae415-B57","doi-asserted-by":"publisher","first-page":"e3647","DOI":"10.1093\/cid\/ciaa1380","article-title":"Rezafungin versus caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis: the STRIVE trial","volume":"73","author":"Thompson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025010610354860900_dkae415-B58","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/cpdd.757","article-title":"Lack of effect of rezafungin on QT\/QTc interval in healthy subjects","volume":"9","author":"Flanagan","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2025010610354860900_dkae415-B59","volume-title":"Activity of a long-acting echinocandin, rezafungin, tested against invasive fungal isolates collected worldwide","author":"Pfaller","year":"2018"},{"key":"2025010610354860900_dkae415-B60","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0140-6736(22)02324-8","article-title":"Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial","volume":"7","author":"Thompson","year":"2023","journal-title":"Lancet"},{"key":"2025010610354860900_dkae415-B61","article-title":"Performance Standards for Antifungal Susceptibility Testing of Yeasts\u2014Third Edition: M27M44S","author":"CLSI","year":"2022"},{"key":"2025010610354860900_dkae415-B62","author":"US Food and Drug Administration"},{"key":"2025010610354860900_dkae415-B63","doi-asserted-by":"publisher","first-page":"e0133923","DOI":"10.1128\/spectrum.01339-23","article-title":"Absence of clinically meaningful drug-drug interactions with rezafungin: outcome of investigations","volume":"11","author":"Flanagan","year":"2023","journal-title":"Microbiol Spectr"},{"key":"2025010610354860900_dkae415-B64","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1016\/S2352-3026(21)00232-5","article-title":"Management of drug-drug interactions of targeted therapies for haematological malignancies and triazole antifungal drugs","volume":"9","author":"Br\u00fcggemann","year":"2022","journal-title":"Lancet Haematol"},{"key":"2025010610354860900_dkae415-B65","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1086\/598327","article-title":"Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents","volume":"48","author":"Br\u00fcggemann","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2025010610354860900_dkae415-B66","volume-title":"Rezafungin safety and pharmacokinetics in subjects with moderate or severe hepatic impairment","author":"Flanagan","year":"2021"},{"key":"2025010610354860900_dkae415-B67","doi-asserted-by":"publisher","first-page":"e01626-16","DOI":"10.1128\/AAC.01626-16","article-title":"Pharmacokinetics of the novel echinocandin CD101 in multiple animal species","volume":"61","author":"Ong","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025010610354860900_dkae415-B68","doi-asserted-by":"publisher","first-page":"e0139021","DOI":"10.1128\/AAC.01390-21","article-title":"Metabolism, excretion, and mass balance of [(14)C]-rezafungin in animals and humans","volume":"66","author":"Ong","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2025010610354860900_dkae415-B69","volume-title":"Of mice and men: comparison of rezafungin versus micafungin lung exposures in mouse, and potential implications for human ELF and efficacy studies","author":"Ong","year":"2018"},{"key":"2025010610354860900_dkae415-B70","doi-asserted-by":"publisher","first-page":"e01009-17","DOI":"10.1128\/AAC.01009-17","article-title":"Unraveling drug penetration of echinocandin antifungals at the site of infection in an intra-abdominal abscess model","volume":"61","author":"Zhao","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025010610354860900_dkae415-B71","doi-asserted-by":"publisher","first-page":"6872","DOI":"10.1128\/AAC.00701-16","article-title":"Preclinical evaluation of the stability, safety, and efficacy of CD101, a novel echinocandin","volume":"60","author":"Ong","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2025010610354860900_dkae415-B72","doi-asserted-by":"publisher","first-page":"S389","DOI":"10.1016\/j.bbmt.2017.12.484","article-title":"CD101 prophylactic dose rationale for prevention of Aspergillus, Candida, and Pneumocystis infections","volume":"24","author":"Flanagan","year":"2018","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/1\/18\/60968252\/dkae415.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/1\/18\/60968252\/dkae415.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T05:36:08Z","timestamp":1736141768000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/1\/18\/7900481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,14]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,11,14]]},"published-print":{"date-parts":[[2025,1,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae415","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,11,14]]}}}